Published in Healthcare Mergers, Acquisitions and Ventures Week, May 1st, 2004
Despite good earnings representing solid performance in a number of life sciences subsectors, it was not enough to overcome the general market malaise that infected both the NASDAQ and the Dow Jones Industrial Average.
"It appears that biotech successes were not enough," said G. Steven Burrill, CEO of Burrill & Company, a San Francisco-based life sciences merchant bank. "Amgen had big earnings, solid revenue growth, and laid out its impressive development plans and pipeline, only to have its price drop 5% on the news. Ultimately, it purchased Tularik...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week